Court Ruling Pressures Stem Cell Stocks

Following Monday's ruling in the Federal District Court for Washington, D.C., to block federal funding for research that uses human embryonic stem cells, companies researching and developing medical techniques involving stem cells saw shares tumble down today across the board.

Pfizer Invests in Stem Cell Therapy

Long an old-line drug company, Pfizer is looking increasingly like a new biotech these days, especially after licensing a stem cell therapy. Athersys' MultiStem is a therapy that consists of a special class of stem cells obtained from the bone marrow of healthy, adult donors to treat inflammatory bowel disease.